US4158052A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-isoglutamine
Assignee: Bpifrance Financement SA
•
Filing: 1975-10-22
•
Granted: 1979-06-12
•
Expires: 1995-10-22
Abstract
Abstract The invention pertains to drug oil-free compositions, notably aqueous injectable compositions acting as non-specific adjuvants to stimulate in a host the immunitary responses to different antigens. The active principle of these oil-free compositions is N-acetyl-muramyl-L-alanyl-D-isoglutamine.
Inventors
- 👤 Francoise Audibert
- 👤 Louis Chedid
- 👤 Pierre LeFrancier
- 👤 Jean Choay
- 👤 Edgar Lederer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 19:02
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/02; C07H15/04; A; A61; A61K; A61K39/00; A61K39/39; C07K; C07K9/00; C07K9/001; C07K9/005; A61K2039/555; A61K2039/55511; A61K2039/5555; A61K38/00
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
19 words
An adjuvant composition comprising an effective amount of N-acetyl muramyl-L-alanyl-D-isoglutamine and a pharmaceutically acceptable carrier, which composition is oil-free.
Claim 2
Dependent Claim
19 words
An adjuvant composition comprising an effective amount of N-acetyl muramyl-L-alanyl-D-isoglutamine and a pharmaceutically acceptable carrier, which composition is oil-free.
Claim 3
Dependent Claim
9 words
The aqueous solution of the composition of claim 1.
Claim 4
Dependent Claim
11 words
The solution of claim 2 which is free of mineral salts.
Claim 5
Dependent Claim
8 words
The solution of claim 2 which is isotonic.
Claim 6
Dependent Claim
8 words
The solution of claim 4 which is sterile.
Claim 7
Dependent Claim
8 words
The solution of claim 2 which is injectable.
Claim 8
Dependent Claim
12 words
The composition of claim 1 which comprises in addition a vaccinating antigen.
Claim 9
Dependent Claim
8 words
The composition of claim 1 which is lyophylized.
Claim 10
Dependent Claim
12 words
The composition of claim 8 which comprises in addition a vaccinating antigen.
Claim 11
Dependent Claim
11 words
The composition of claim 7 wherein the carrier is a solid.
Claim 12
Dependent Claim
11 words
The composition of claim 10 which is suitable for oral administration.
Claim 13
Dependent Claim
11 words
The composition of claim 10 which is suitable for rectal administration.
Claim 14
Dependent Claim
14 words
The composition of claim 1 in suspension form in a liquified propellant type gas.
Claim 15
Dependent Claim
11 words
The composition of claim 9 which is suitable for vaginal administration.
Claim 16
Dependent Claim
15 words
The composition of claim 7 which is suitable for nasal, ocular or vaginal local administration.
Claim 17
Dependent Claim
21 words
The composition of claim 1 wherein the N-acetyl muramyl-L-alanyl-D-isoglutamine is present in the range from about 10 to about 200 mg.
Claim 18
Dependent Claim
16 words
The composition of claim 16 wherein the range is from about 30 to about 100 mg.
Claim 19
Dependent Claim
13 words
The composition of claim 16 which is an injectable isotonic sodium chloride solution.
Claim 20
Dependent Claim
30 words
The process which comprises treating a subject with the composition of claim 1 to increase the production of circulating antobides in vivo without developing a sensitizing reaction in the subject.
Claim 21
Dependent Claim
37 words
The process of claim 19 wherein the subject has previously been exposed to at least one adjuvant selected from the group consisting of N-acetyl muramyl-L-alanyl-D-isoglutamine, mycobacteria or mycobacterial extracts, or an adjuvant extractable from mycobacteria or Nocardia.
Claim 22
Dependent Claim
11 words
The process of claim 19 wherein the composition is a solution.
Claim 23
Dependent Claim
12 words
The process of claim 19 wherein the composition is a reconstituted lyophilisate.
Claim 24
Dependent Claim
20 words
The process of claim 19 wherein the composition is used in an amount sufficient to have a non-specific adjuvant effect.
Claim 25
Dependent Claim
12 words
The composition of claim 9 wherein the antigen is a weak immunogen.
Claim 26
Dependent Claim
10 words
The method of claim 23 wherein the administration is oral.
Claim 27
Dependent Claim
14 words
The method of claim 23 wherein the administration is in a pharmaceutically acceptable aerosol.
Claim 28
Dependent Claim
18 words
A physiologically active composition which comprises an effective amount of N-acetyl-muramyl-L-alanyl-D-isoglutamine in a physiological serum free of oil.
Claim 29
Dependent Claim
18 words
A physiologically active composition which comprises an effective amount of N-acetyl-muramyl-L-alanyl-D-isoglutamine in a physiological serum free of oil.
Claim 30
Dependent Claim
20 words
A physiologically active composition which comprises an effective amount of N-acetyl-muramyl-L-alanyl-D-isoglutamine in a physiological aqueous glucose solution free of oil.
Claim 31
Dependent Claim
20 words
A physiologically active composition which comprises an effective amount of N-acetyl-muramyl-L-alanyl-D-isoglutamine in a physiological aqueous glucose solution free of oil.
Claim 32
Independent Claim
39 words
A method for stimulating an immune response in a host which comprises administering to the host an effective amount of a composition free of oil comprising N-acetyl-muramyl-L-alanyl-D-isoglutamine and an antigen, thereby increasing the production of circulating antibodies in vivo.
Claim 33
Independent Claim
39 words
A method for stimulating an immune response in a host which comprises administering to the host an effective amount of a composition free of oil comprising N-acetyl-muramyl-L-alanyl-D-isoglutamine and an antigen, thereby increasing the production of circulating antibodies in vivo.
Claim 34
Dependent Claim
21 words
The method of claim 29 wherein the administration is performed in conjunction with the administration of a vaccine to the host.
Claim 35
Dependent Claim
39 words
A therapeutic method for stimulating an immune response in a host without causing an immunogenic reaction in the host, which comprises administering to the host an effective amount of a composition free of oil comprising N-acetyl-muramyl-L-alanyl-D-isoglutamine and a carrier.
Claim 36
Dependent Claim
39 words
A therapeutic method for stimulating an immune response in a host without causing an immunogenic reaction in the host, which comprises administering to the host an effective amount of a composition free of oil comprising N-acetyl-muramyl-L-alanyl-D-isoglutamine and a carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-06-11 | 1982-12-11 | 1983-06-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-06-11 | 1986-12-11 | 1987-06-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-06-11 | 1990-12-11 | 1991-06-12 | $7700.00 | Window Closed / Lapsed |